Press Announcements > Statement from FDA’s Donald St. Pierre on findings from ongoing investigation into lead testing issues
Statement from FDA’s Donald St. Pierre on findings from ongoing investigation into lead testing issues
BD studies find chemical interaction during test processing may contribute to skewing results
When the U.S. Food and Drug Administration first warned Americans in May 2017 that lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the U.S., the agency made a commitment to continue to aggressively investigate the problem. Since then, the FDA has remained in close contact with the lead test manufacturer as well as Becton Dickinson (BD) & Company, the manufacturer of certain blood sample collection tubes often used alongside many lead tests, as part of our effort to determine the cause of the inaccurate results.Continue reading.